At the initial stage of acetylleucine manufacture, DL-leucine is converted to N-acetyl-DL-leucine through a pH-controlled acylation that relies on aqueous alkaline conditions rather than isolated acid chloride or anhydrous solvent systems. The reaction is monitored continuously with a glass pH electrode inserted through the reactor lid, and the release specification is defined by Ph. Eur. 10.0 2.2.20 for potentiometric assay, Ph. Eur. 2.5.12 for water content, and ICH Q3C(R8) for residual solvents in the dried active substance. Finished acetylleucine intended for vestibular-disorder dosage forms is treated as an active pharmaceutical ingredient under EU GMP Part II and is normally released against the current Ph. Eur. monograph for acetylleucine, with additional residual acetic acid limits derived from process validation data. The impurity profile is dominated by unreacted leucine and acetate salts, both of which are controlled by ion-pair HPLC using method parameters aligned with Ph. Eur. 2.2.46. Process documentation generated during technology transfer to CMO sites typically includes a deviation log for pH excursions, jacket temperature alarms, and filtration cycles because these three variables account for most batch-to-batch variance in yield and particle behaviour.

The charging ratio on a production-scale batch is 1.0 mol DL-leucine to 1.05–1.15 mol acetic anhydride, with the leucine initially dissolved in 3.0–4.0 L purified water per kg of substrate. Aqueous sodium hydroxide solution at 30% w/w is metered simultaneously to keep the reaction mixture at pH 9.5–10.5, while the jacket is held at 15–25°C to suppress exotherm-driven hydrolysis. The acetic anhydride is added through a peristaltic pump over 60–120 min; a dosing interval below 60 min can produce transient pH collapse below 9.0, causing incomplete acetylation, whereas an interval above 120 min prolongs alkaline exposure and increases leucine regeneration. After reaction, the mixture is neutralised to pH 5.0–5.8 with hydrochloric acid, and the precipitated acetylleucine is separated on a plate-and-frame filter fitted with 15–25 µm polypropylene filter cloths, displacement-washed with chilled purified water at 2–5°C, and discharged with a residual solvent content of 25–35% water before drying. On isolated campaigns where the filter cloth blinds, the filtration cycle extends to 4–6 h and can reduce daily throughput by 20–30%, which is why multiple filter cloth sets are kept in the changeover inventory. The process is defined for a glass-lined reactor of 2000–5000 L working volume; use of unlined stainless steel is not recommended because residual acetate in the wet filter cake can promote surface corrosion over repeated campaign intervals.

Drying is performed in a conical vacuum dryer at 60–65°C and 50–100 mbar absolute pressure until the Karl Fischer moisture result is ≤0.5%. The dried material is subsequently milled in a pin mill or jet mill to a particle-size distribution with D90 ≤75 µm for tablet formulations; milling is omitted when the lot is assigned to solution manufacturing because particle size does not govern dissolution. Batch-to-batch variance in particle size during high-speed rotary tablet pressing at 80–120 rpm has been observed to alter die-fill consistency when the angle of repose exceeds 40°, and pre-blending with a colloidal silica flow aid is applied only when the customer formulation permits it. Terminal finished products are acetylleucine-containing oral tablets and injectable solutions for vestibular indications; where tablets are compressed, the formulation is validated for content uniformity according to Ph. Eur. 2.9.40. The critical operational boundary is moisture: if the drying endpoint exceeds 0.5%, subsequent milling generates cohesive agglomerates that reduce sieve throughput. Reprocessing of oversized mill fractions must be recorded as a deviation under ICH Q7, and storage in unlined steel vessels should be avoided because residual acetate can initiate localised pitting. Published data for this specific configuration is limited with respect to long-term milled-particle stability, so real-time stability protocols at 25°C/60% RH and 40°C/75% RH are employed to justify retest intervals.

What Process Controls Prevent Premature Fmoc Cleavage During Schotten-Baumann Protection?

DL-leucine is converted to Fmoc-DL-leucine for use as a protecting-group reagent in solid-phase peptide synthesis when a leucine residue is required in early-stage sequence screening and chiral specification is not a release criterion for the target peptide. The release specification relies on USP <621> and Ph. Eur. 2.2.46 for chromatographic purity, Ph. Eur. 2.5.12 for water content, and ICH Q3C(R8) for residual 1,4-dioxane. The ICH limit for 1,4-dioxane is 3.8 mg/day, which imposes a specific batch control because the reaction solvent is dioxane-rich and must be reduced by repeated ethyl acetate extraction and vacuum drying. The analytical method is gradient reversed-phase HPLC with UV detection at 254 nm; the target compound and Fmoc-OH hydrolysis product are resolved only when the mobile phase acetonitrile gradient is held below 0.8%/min within the critical elution window.

The production charge is 1.0 mol DL-leucine, 1.1–1.5 mol Fmoc-OSu, and 2.0–2.5 mol sodium carbonate in a dioxane/water mixture of 1:1.5 v/v. The suspension is initially cooled to 0–5°C before Fmoc-OSu addition, then warmed to 20–25°C and held for 2–4 h. A pH-stat is set to 8.5–9.0; if the controller overshoots beyond 10.0, the Fmoc group begins to cleave, releasing dibenzofulvene and giving the mother liquor a yellow-orange colour that is visible during in-process inspection. The reactor is a 1000 L glass-lined vessel with baffles and a retreat-curve impeller; the Fmoc-OSu is metered as a dioxane slurry through a peristaltic hose pump to avoid localised high-alkalinity zones near the addition nozzle. After reaction, the mixture is acidified with dilute hydrochloric acid to pH 2.0, extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated in a rotary evaporator at 35–40°C before crystallisation from ethyl acetate/n-heptane at −5 to 0°C. Isolation occurs in a pressure nutsche filter under nitrogen, and the wet cake is washed with pre-chilled n-heptane to remove dibenzofulvene-associated colour bodies.

The isolated Fmoc-DL-leucine is dried in a vacuum tray dryer at 40°C to ≤0.5% moisture and packaged in LDPE-lined fibre drums. It is used in automated peptide synthesizers operating between 0.1 mmol and 10 mmol scale, typically in Fmoc/tBu solid-phase synthesis for research peptide libraries, early-stage therapeutic peptide process development, and peptide-grafted resin intermediates. Because the DL-racemate is not suitable for peptide sequences where enantiopurity is a release parameter, its use is confined to non-clinical screening, process development, or analytical method development. Terminal product types include crude peptide candidates, intermediate protected peptide fragments, and N-terminal leucine-bearing model peptides cleaved with trifluoroacetic acid-based cocktails and subsequently lyophilised. Moisture in the dioxane charge above 0.1% suppresses conversion and increases the Fmoc-OH hydrolysis product, which co-elutes with the target compound in isocratic HPLC unless gradient conditions are adjusted. The process should not be executed in steel vessels without glass lining because the sodium carbonate and brine washes create a chloride-rich alkaline environment that accelerates corrosion at the agitator hub.

After the acetylleucine fraction is isolated, a parallel downstream route uses the racemic N-acetyl-DL-leucine as a resolution substrate. Acylase I, a zinc-dependent aminoacylase classified as EC 3.5.1.14, selectively hydrolyses N-acetyl-L-leucine to L-leucine while leaving N-acetyl-D-leucine intact. The resolution is run at 15–25% w/v substrate concentration, with enzyme loading of 1500–3000 U/L, at 37–45°C and pH 7.0–7.5, with pH maintained by ammonia or dilute sodium hydroxide titration. Agitation is provided by a low-shear anchor impeller at 150–300 rpm to avoid enzyme denaturation at the gas-liquid interface. The enzymatic reaction is monitored by thin-layer chromatography under Ph. Eur. 2.2.27, and the endpoint is confirmed when the ninhydrin-positive L-leucine spot no longer increases in intensity over two consecutive hourly samples.

The L-leucine generated during hydrolysis is recovered by cation-exchange chromatography on a strong-acid resin in ammonium ion form, followed by ammonia-water elution and crystallisation at pH 5.9–6.1. The residual N-acetyl-D-leucine is then hydrolysed with 2 M hydrochloric acid at reflux for 4–6 h, neutralised with ammonia, decolourised with activated carbon, and crystallised from water/ethanol. The release of L-leucine is verified by Ph. Eur. 2.2.7 optical rotation against a certified reference lot; accepted values fall between +14.9° and +15.8° for the L-isomer and the corresponding negative range for the D-isomer. Additional identity testing uses infrared absorption and a ninhydrin-positive thin-layer chromatogram. Process water quality is controlled to compendial grade because trace metal contamination at the ion-exchange step can displace ammonium counterions and reduce binding capacity by more than 10% across a resin campaign.

Terminal output consists of D-leucine for chiral building-block synthesis, particularly in peptide mimetic research and enantiopure analytical controls, and L-leucine for cell culture media, parenteral nutrition raw material, and pharmaceutical-grade amino acid premixes. Process boundaries include the chelating agents: EDTA at 1 mM or higher strips the catalytic zinc ion and reduces enzyme activity by more than 50%; substrate concentrations above 30% w/v produce substrate inhibition; pH below 6.5 reduces enantioselectivity because both acetylated enantiomers begin to hydrolyse. The hydrolysis vessel should not be cleaned with hypochlorite-based oxidising agents because residual chlorine modifies the enzyme active site and shortens campaign life. For D-leucine batches used as chiral controls, an enantiomeric excess specification of ≥ 98.0% is applied using chiral HPLC, and the result must be stated on the certificate of analysis because downstream peptide coupling can shift the impurity profile if the L-isomer content exceeds the release threshold.

Solubility and Electrostatic Constraints in Amino Acid Hair-Conditioning Systems

Cosmetic-grade DL-leucine is listed in the EU CosIng database as Leucine with antistatic, hair conditioning, and skin conditioning functions. Under Regulation (EC) No 1223/2009, the raw material is not subject to an Annex II or Annex III restriction, but the manufacturing site is expected to operate under ISO 22716:2007 GMP guidance. Formulators add DL-leucine to the aqueous phase before emulsification at 60–65°C; the material is allowed to dissolve completely for 15–20 min under propeller mixing at 200–400 rpm. In rinse-off conditioners and hair masks, the addition ratio is typically 0.5–2.0 wt%; in leave-on serums and sprays, the loading is reduced to 0.1–0.8 wt% to avoid crystalline deposits on hair fibres at 25°C. The final formulation is adjusted to pH 4.5–5.5 with a 10% citric acid solution after cooling to 35–40°C, and homogenised at 3000–5000 rpm for 10–15 min in a rotor-stator mixer. Final performance is evaluated in a controlled humidity chamber at 40% RH and 22°C using combing force and surface potential readings to verify that static charge reduction is retained under dry ambient conditions.

Terminal cosmetic product types include amino acid-based shampoos, silicone-free leave-on conditioners, antistatic hair serums, and barrier-repair skin creams. In shampoos containing anionic surfactant systems, DL-leucine is pre-dissolved in water before surfactant addition to prevent pH shock and localised precipitation; the surfactant load is typically 8–12% active matter for clear liquid shampoos. In leave-on sprays, a co-solvent such as propylene glycol at 1–3 wt% is often used when the DL-leucine addition exceeds 0.5 wt% to maintain solubility during 30-day stability storage at 5°C. Cold-cycle testing is mandatory because leucine exhibits minimum solubility near its isoelectric point, and formulations buffered above pH 6.0 are at greater risk of crystalline precipitation. Compatibility with strong oxidising dye bases is not established; in formulations containing hydrogen peroxide above 3%, published data for this specific configuration is limited, and a separate stability protocol should be executed before scale-up.